An investigation for investors in HUTCHMED (China) Limited (NASDAQ:HCM) shares over potential securities laws violations by HUTCHMED (China) Limited was announced.

San Diego, CA -- (SBWire) -- 05/16/2022 --HUTCHMED (China) Limited is under investigation over potential securities laws violations in connection with certain financial statements.

Investors who purchased shares of HUTCHMED (China) Limited (NASDAQ: HCM), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by HUTCHMED (China) Limited regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Hong Kong based HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally.

HUTCHMED (China) Limited reported that its annual Total Revenue rose from $227.97 million in 2020, to $356.12 million in 2021, and that its Net Loss increased from $125.73 million in 2020,, to $194.64 million in 2021.

On May 2, 2022, HUTCHMED (China) Limited announced that the U.S. Food and Drug Administration ("FDA") rejected Hutchmed's application seeking approval of surufatinib to treat certain neuroendocrine tumors, noting that the data submitted did not support an approval and a multi-regional clinical trial is required.

Shares of HUTCHMED (China) Limited (NASDAQ: HCM) declined to as low as $9.82 per share on May 10, 2022.

Those who purchased shares of HUTCHMED (China) Limited (NASDAQ: HCM) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Christopher Clausen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.